"Iron Overload and Endocrinological Diseases"

Sponsor
Azienda Ospedaliero-Universitaria di Modena (Other)
Overall Status
Recruiting
CT.gov ID
NCT06137079
Collaborator
(none)
62
1
150.4
0.4

Study Details

Study Description

Brief Summary

Patients with hemochromatosis or Thalassemia develop progressive tissue and organs damages secondary to iron overload. Iron overload can result both from transfusional hemosiderosis and excess gastrointestinal iron absorption. Iron deposition in the heart, liver, and multiple endocrine glands results in severe damage to these organs, with variable degrees of endocrine and organ failure.

Although patients with iron overload often present endocrine disorders, the pathogenetic mechanisms underlying endocrinopathies are not completely clear. In particular it is not elucidated if the spectrum of endocrinopathies could change with advancing age. All endocrinological comorbidities can develop from a primary damage of the target gland, from pituitary secondary failure or from both.

The aim of this study is to investigate the prevalence of endocrinological diseases in adult patients with iron overload due to β-thalassemia or hemochromatosis and their impact on well-being and quality of life.

The study design is a prospective cross-sectional clinical study. All subjects enrolled will be evaluated for the endocrine diseases. The study protocol will include data collection from family and patients' history of diseases, physical examination, hormonal assessment for all endocrine axes and instrumental examinations.

The results will provide evidence on the prevalence of endocrine diseases in patients with iron overload and will add information to characterize the type and the degree of endocrine deficiencies, and on the pathogenic mechanisms involved, in order to individualize diagnostic and therapeutic approaches.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    62 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    "Iron Overload and Endocrinological Diseases"
    Study Start Date :
    Jun 20, 2013
    Anticipated Primary Completion Date :
    Dec 31, 2024
    Anticipated Study Completion Date :
    Dec 31, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Estimate prevalence of endocrine comorbidities of β-thalassemia in adulthood [12 years]

    Secondary Outcome Measures

    1. Evaluate prevalence of endocrine diseases to characterize the type and the degree of endocrine deficiencies [12 years]

    2. Evaluate incidence of endocrine diseases to characterize the type and the degree of endocrine deficiencies [12 years]

    3. To investigate the relationships among iron status and endocrine alterations in these group of patients [12 years]

    4. To investigate the relationships among iron status and cardiac disease in these group of patients [12 years]

    5. To investigate the relationships among iron status and liver disease in these group of patients [12 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Certain diagnosis of β-thalassemia major or intermedia

    • Certain diagnosis of Hereditary Hemochromatosis

    • Adult patients with an age between 18 and 65 years

    Exclusion Criteria:
    • Subjects with an age < 18 and > 65 years

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Unit of Endocrinology of Azienza Ospedaliero-Universitaria di Modena Modena Italy

    Sponsors and Collaborators

    • Azienda Ospedaliero-Universitaria di Modena

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Vincenzo Rochira, Professor, Azienda Ospedaliero-Universitaria di Modena
    ClinicalTrials.gov Identifier:
    NCT06137079
    Other Study ID Numbers:
    • 24/13
    First Posted:
    Nov 18, 2023
    Last Update Posted:
    Nov 18, 2023
    Last Verified:
    Nov 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 18, 2023